NCT05799274View on ClinicalTrials.gov

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Healthy VolunteersPancreatic Ductal Adenocarcinoma
Interventions
DRUG

RAD301 ([68Ga]-RAD301)

A single dose of 68Ga-RAD301 of 150 +/- 50 MBq (\~4mCi) administered as a slow bolus injection over 2-5 minutes

Trial Locations (2)

10461

RECRUITING

Montefiore Medical Center, The Bronx

08540

RECRUITING

United Theranostics, Princeton

All Listed Sponsors
lead

Radiopharm Theranostics, Ltd

INDUSTRY